Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6967)
All Articles published online
|
Publishing Process of This Article
|
Jun 26, 2014 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Methodology
ISSN
2222-0682
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ria R, Reale A, Vacca A. Novel agents and new therapeutic approaches for treatment of multiple myeloma. World J Methodol 2014; 4(2): 73-90 [PMID: 25332907 DOI: 10.5662/wjm.v4.i2.73] |
|---|---|
| URL: | https://www.wjgnet.com/2222-0682/full/v4/i2/73.htm |
| Number | Citing Articles |
| 1 |
FUMIAKI KITAZAWA, YOKO KADO, KUMI UEDA, TAKATOSHI KOKUFU, SHIN-ICHI FUCHIDA, AKIRA OKANO, MAYUMI HATSUSE, SATOSHI MURAKAMI, YUKO NAKAYAMA, KOHJI TAKARA, CHIHIRO SHIMAZAKI. The interaction between oral melphalan and gastric antisecretory drugs: Impact on clinical efficacy and toxicity. Molecular and Clinical Oncology 2016; 4(2): 293 doi: 10.3892/mco.2015.683
|
| 2 |
Yura Lee, Jung-Il Jung, Kyeong-Yong Park, Soon Ae Kim, Jiyeon Kim. Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells. Oncotarget 2017; 8(25): 41091 doi: 10.18632/oncotarget.17056
|
| 3 |
Yuying Li, Zhonghua Du, Xu Wang, Guanjun Wang, Wei Li. Association ofIL-6Promoter and Receptor Polymorphisms with Multiple Myeloma Risk: A Systematic Review and Meta-Analysis. Genetic Testing and Molecular Biomarkers 2016; 20(10): 587 doi: 10.1089/gtmb.2015.0169
|
| 4 |
P G Richardson, C C Hofmeister, N S Raje, D S Siegel, S Lonial, J Laubach, Y A Efebera, D H Vesole, A K Nooka, J Rosenblatt, D Doss, M H Zaki, A Bensmaine, J Herring, Y Li, L Watkins, M S Chen, K C Anderson. Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. Leukemia 2017; 31(12): 2695 doi: 10.1038/leu.2017.173
|
| 5 |
Antonia Reale, Tiffany Khong, Sridurga Mithraprabhu, Andrew Spencer. Translational Potential of RNA Derived From Extracellular Vesicles in Multiple Myeloma. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.718502
|
| 6 |
Ilaria Saltarella, Fortunato Morabito, Nicola Giuliani, Carolina Terragna, Paola Omedè, Antonio Palumbo, Sara Bringhen, Lorenzo De Paoli, Enrica Martino, Alessandra Larocca, Massimo Offidani, Francesca Patriarca, Chiara Nozzoli, Tommasina Guglielmelli, Giulia Benevolo, Vincenzo Callea, Luca Baldini, Mariella Grasso, Giovanna Leonardi, Manuela Rizzo, Antonietta Pia Falcone, Daniela Gottardi, Vittorio Montefusco, Pellegrino Musto, Maria Teresa Petrucci, Franco Dammacco, Mario Boccadoro, Angelo Vacca, Roberto Ria. Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. Journal of Hematology & Oncology 2019; 12(1) doi: 10.1186/s13045-018-0691-4
|
| 7 |
Suelen Vigolo, Joice Zuckermann, Rosane Isabel Bittencourt, Lúcia Silla, Diogo André Pilger. Comparison of cyclophosphamide–thalidomide–dexamethasone to bortezomib–cyclophosphamide–dexamethasone as induction therapy for multiple myeloma patients in Brazil. Hematology/Oncology and Stem Cell Therapy 2017; 10(3): 135 doi: 10.1016/j.hemonc.2017.05.027
|
| 8 |
M.A. Koenders, R. Saso. A mathematical model of cell equilibrium and joint cell formation in multiple myeloma. Journal of Theoretical Biology 2016; 390: 73 doi: 10.1016/j.jtbi.2015.11.013
|
| 9 |
Muhammad Bilal Abid, Sanjay De Mel, Muhammad Abbas Abid, Kong Bing Tan, Wee Joo Chng. Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence. Cancer Biology & Therapy 2016; 17(7): 723 doi: 10.1080/15384047.2016.1178427
|
| 10 |
Joelle C. Boulos, Mohamed E. M. Saeed, Manik Chatterjee, Yagmur Bülbül, Francesco Crudo, Doris Marko, Markus Munder, Sabine M. Klauck, Thomas Efferth. Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells. Pharmaceuticals 2021; 14(11): 1126 doi: 10.3390/ph14111126
|
| 11 |
Han Yan, Su Gao, Aoshuang Xu, Liping Zuo, Jiasi Zhang, Yuhong Zhao, Qianwen Cheng, Xuejiao Yin, Chunyan Sun, Yu Hu. MALAT1 regulates network of microRNA-15a/16–VEGFA to promote tumorigenesis and angiogenesis in multiple myeloma. Carcinogenesis 2023; 44(10-11): 760 doi: 10.1093/carcin/bgad053
|
| 12 |
Jona Van der Straeten, Wouter De Brouwer, Emmanuelle Kabongo, Marie-Françoise Dresse, Karel Fostier, Rik Schots, Ivan Van Riet, Marleen Bakkus. Validation of a PCR-Based Next-Generation Sequencing Approach for the Detection and Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia and Multiple Myeloma Using gBlocks as Calibrators. The Journal of Molecular Diagnostics 2021; 23(5): 599 doi: 10.1016/j.jmoldx.2021.01.009
|
| 13 |
Roberto Ria, Antonio Solimando, Assunta Melaccio, Azzurra Sportelli, Angelo Vacca. Update on Multiple Myeloma. 2019; doi: 10.5772/intechopen.76931
|
| 14 |
Noemi Horvath, Andrew Spencer, Melita Kenealy, Douglas Joshua, Philip J Campbell, Je-Jung Lee, Jian Hou, Lugui Qiu, Anna Kalff, Tiffany Khong, Anil Londhe, Sarah Siggins, Maximiliano van Kooten Losio, Michael Eisbacher, H. Miles Prince. Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study. Leukemia & Lymphoma 2019; 60(9): 2122 doi: 10.1080/10428194.2019.1579322
|
| 15 |
Ying Fang, Ruonan Xu, Bing Zhai, Chunmei Hou, Ning Ma, Liang Wang, Gencheng Han, Zhenyu Jiang, Renxi Wang. Gm40600 suppressed SP 2/0 isograft tumor by reducing Blimp1 and Xbp1 proteins. BMC Cancer 2019; 19(1) doi: 10.1186/s12885-019-5848-1
|
| 16 |
Masahiro Kizaki, Takayuki Tabayashi. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches. Journal of Clinical and Experimental Hematopathology 2016; 56(1): 20 doi: 10.3960/jslrt.56.20
|
| 17 |
Fatma Necmiye Kacı, Yağmur Kiraz, Demet Çekdemir, Yusuf Baran. Synergistic Apoptotic Effects of Bortezomib and Methylstat on Multiple Myeloma Cells. Archives of Medical Research 2020; 51(3): 187 doi: 10.1016/j.arcmed.2020.01.012
|
| 18 |
Hae Jung Chon, Yura Lee, Kyoung Jun Bae, Byung Jin Byun, Soon Ae Kim, Jiyeon Kim. Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells. Amino Acids 2016; 48(7): 1591 doi: 10.1007/s00726-016-2214-3
|
| 19 |
Shan Meng, Chenyang Lu, Wanggang Zhang, Wenjun Shen, Yongchang Wei, Dan Su, Fuling Zhou. MMSA-1 expression pattern in multiple myeloma and its clinical significance. Clinical and Experimental Medicine 2016; 16(4): 599 doi: 10.1007/s10238-015-0393-y
|
| 20 |
Lisha Zheng, Ang Zhang, Jishan Liu, Min Liu, Yikun Zhang. HDAC1 promotes the migration of human myeloma cells via regulation of the lncRNA/Slug axis. International Journal of Molecular Medicine 2021; 49(1) doi: 10.3892/ijmm.2021.5058
|
| 21 |
Roberto Ria, Assunta Melaccio, Vito Racanelli, Angelo Vacca. Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients. Journal of Clinical Medicine 2020; 9(6): 1765 doi: 10.3390/jcm9061765
|
| 22 |
Alessio Malacrida, Daniele Maggioni, Arianna Cassetti, Gabriella Nicolini, Guido Cavaletti, Mariarosaria Miloso. Antitumoral Effect of Hibiscus sabdariffa on Human Squamous Cell Carcinoma and Multiple Myeloma Cells. Nutrition and Cancer 2016; 68(7): 1161 doi: 10.1080/01635581.2016.1208830
|
| 23 |
Bing Zhai, Chunmei Hou, Ruonan Xu, Ying Fang, He Xiao, Guojiang Chen, Xiaoqian Wang, Ning Ma, Gencheng Han, Renxi Wang. Loc108167440 suppressed myeloma cell growth by P53-mediated apoptosis. Leukemia & Lymphoma 2019; 60(10): 2541 doi: 10.1080/10428194.2019.1590572
|
| 24 |
MOF-based nanocomposites as transduction matrices for optical and electrochemical sensing. Talanta 2024; 266: 125124 doi: 10.1016/j.talanta.2023.125124
|
| 25 |
Jianbiao Zhou, Wee-Joo Chng. Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma. World Journal of Clinical Oncology 2019; 10(9): 303-306 doi: 10.5306/wjco.v10.i9.303
|
| 26 |
Katherine A. Staines, Matt Prideaux, Steve Allen, David J. Buttle, Andrew A. Pitsillides, Colin Farquharson. E11/Podoplanin Protein Stabilization Through Inhibition of the Proteasome Promotes Osteocyte Differentiation in Murine in Vitro Models. Journal of Cellular Physiology 2016; 231(6): 1392 doi: 10.1002/jcp.25282
|
| 27 |
Katherine A. Staines, Ekele Ikpegbu, Anna E. Törnqvist, Scott Dillon, Behzad Javaheri, Anish K. Amin, Dylan N. Clements, David J. Buttle, Andrew A. Pitsillides, Colin Farquharson. Conditional deletion of E11/podoplanin in bone protects against load-induced osteoarthritis. BMC Musculoskeletal Disorders 2019; 20(1) doi: 10.1186/s12891-019-2731-9
|